PIPERACILLIN/TAZOBACTAM PLUS AMIKACIN VERSUS CARBAPENEM MONOTHERAPY AS EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES

REFERENCES

• Elting L S, Rubenstein E B, Rolston K VI. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25: 247–259
   PubMed Web of Science ®Google Scholar
• Schimpf S C. Infections in cancer patients. Principles and Practice of Infectious Diseases, G L Mandell, R G Douglas, J E Benett. Churchill Livingstone, London 1995; 2666–2675
   Google Scholar
• Hughes W T, Armstrong D, Bodey G P, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751
   PubMed Web of Science ®Google Scholar
• Cometta A, Glauser M P. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. J Chemother 1996; 8: 375–381
   PubMed Web of Science ®Google Scholar
• Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto Infection Program. Antimicrob Agents Chemother 1996; 40: 1108–1115
   PubMed Web of Science ®Google Scholar
• Hung K C, Chiu H H, Tseng Y C, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect 2003; 36: 254–259
   PubMedGoogle Scholar
• Le Guyader N, Auvrignon A, Vu-Thien H, Portier E, Tabone M D, Leverger G. Piperacillin–tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer 2004; 12: 720–724
   PubMed Web of Science ®Google Scholar
• Del F A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis. 2001; 33: 1295–1301
   PubMedGoogle Scholar
• Viscoli C, Cometta A, Kern W V, et al. Piperacillin–tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006; 12: 212–216
   PubMed Web of Science ®Google Scholar
• Duzova A, Kutluk T, Kanra G, et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr. 2001; 43: 105–109
   PubMed Web of Science ®Google Scholar
• Bauduer F, Cousin T, Boulat O, et al. A randomized prospective multicentre trial of cefpirome versus piperacillin–tazobactam in febrile neutropenia. Leuk Lymphoma 2001; 42: 379–386
   PubMed Web of Science ®Google Scholar
• Alexander S W, Walsh T J, Freifeld A G, Pizzo P A. Infectious complications in the pediatric cancer patients. Principles and Practice of Pediatric Oncology 4th ed., P A Pizzo, D G Poplack. Lippincott Williams & Wilkins, Philadelphia 2002; 1239–1283
   Google Scholar
• Elting L S, Rubenstein E B, Rolston K V, Bodey G P. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25: 247–259
   PubMed Web of Science ®Google Scholar
• Petrilli A S, Bianchi A, Kusano E, et al. Fever and granulocytopenia in children with cancer: a study of 299 episodes with two treatment protocols in Brazil. Med Pediatr Oncol. 1993; 21: 356–361
   PubMedGoogle Scholar
• Lucas K G, Brown A E, Armstrong D, Chapman D, Heller G. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77: 791–798
   PubMed Web of Science ®Google Scholar
• Hess U, Bohme C, Rey K, Senn H J. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998; 6: 402–409
   PubMed Web of Science ®Google Scholar
• Cometta A, Zinner S, de B R, et al. Piperacillin–tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39: 445–452
   PubMed Web of Science ®Google Scholar
• Aksoylar S, Cetingul N, Kantar M, Karapinar D, Kavakli K, Kansoy S. Meropenem plus amikacin versus piperacillin–tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol. 2004; 21: 115–123
   PubMed Web of Science ®Google Scholar
• Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol. 2006; 23: 177–186
   PubMed Web of Science ®Google Scholar
• Rossini F, Terruzzi E, Verga L, et al. A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. Support Care Cancer 2005; 13: 387–392
   PubMed Web of Science ®Google Scholar